logo-loader
viewAstraZeneca

Hat-trick for AstraZeneca as its cancer and anaemia drugs come up trumps in three late-stage trials

Lynparza improved response rates in a subset of ovarian cancer patients, while Roxadustat boosted haemoglobin count in people with anaemia

green traffic light
It has been a busy week for Astra and those two drugs

AstraZeneca PLC (LON:AZN) bagged itself a hat-trick on Thursday after its ovarian cancer and anaemia drugs met their goals in three separate late-stage trials.

The results should be a boon for the blue-chip drugmaker, which has seen patents on several of its blockbuster drugs expire in recent years, severely denting sales.

READ: Chinese regulators approve Astra’s Roxadustat drug

But shares were down 1.5% on Thursday morning to 5,878p as they followed the FTSE 100 lower, which dropped to two-year lows.

Lynparza, Astra’s cancer drug which it is developing alongside Merck, improved response rates in patients with relapsed ovarian cancer who had previously received chemotherapy.

The company said it will discuss the results with US regulators, who recently approved Lynparza as a first-line treatment in adults with a slightly different type of ovarian cancer.

As for AstraZeneca’s Roxadustat anaemia treatment, that also met its primary endpoint in two separate trials exploring its effectiveness in boosting haemoglobin count in patients with the blood disorder.

It marks a successful week for the drug, which was approved for use in China on Tuesday.

Quick facts: AstraZeneca

Price: 7383 GBX

LSE:AZN
Market: LSE
Market Cap: £968.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

NQ Minerals' David Lenigas focused on restructuring debt and upping profits...

NQ Minerals PLC's (LON:NQMI) David Lenigas speaks to Proactive London's Andrew Scott soon after taking over as chairman at the Australia-focused mining group. Production and exploration plans aside, Lenigas also says they're in advanced talks to replace on more favourable terms all the debt...

3 hours, 30 minutes ago

2 min read